Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1092-1100

  Daud, Adil I ^a,j   Krishnamurthi, Smitha S ^b   Saleh, Mansoor N ^c   Gitlitz, Barbara J ^d   Borad, Mitesh J ^e   Gold, Philip J ^f   Chiorean, Elena G ^g   Springett, Gregory M ^a   Abbas, Richat ^h   Agarwal, Shefali ^h   Bardy Bouxin, Nathalie ^h   Hsyu, Poe Hirr ^h   Leip, Eric ^h   Turnbull, Kathleen ^h   Zacharchuk, Charles ^h   Messersmith, Wells A ^i,k  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c Georgia Cancer Specialists   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h PFIZER INC   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF COLORADO CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; NITRILES; PROTEIN KINASE INHIBITORS; QUINOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857090723     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2378     Document Type: Article

References (31)

1. Varmus H, Hirai H, Morgan D, Kaplan J, Bishop JM. Function, location, and regulation of the src protein-tyrosine kinase. Princess Takamatsu Symp 1989;20:63-70.
2. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80. (Pubitemid 38745532)
3. Trevino JG, Summy JM, Gallick GE. SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 2006;6:681-7. (Pubitemid 43881119)
4. Abram CL, Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000;254:1-13. (Pubitemid 30066726)
5. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-42.
6. Boschelli DH, Wang YD, Johnson S, Wu B, Ye F, Barrios Sosa AC, et al. 7-Alkoxy-4-phenylamino-3-quinolinecar-bonitriles as dual inhibitors of Src and Abl kinases. J Med Chem 2004;47:1599-601. (Pubitemid 38380903)
7. Boschelli F, Arndt K, Gambacorti-Passerini C. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia. Eur J Cancer 2010;46:1781-9.
8. Messersmith WA, Rajeshkumar NV, Tan AC, Wang XF, Diesl V, Choe SE, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009;8:1484-93.
9. Rabbani SA, Valentino ML, Arakelian A, Ali S, Boschelli F. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther 2010;9:1147-57.
10. Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008;7:1185-94.
11. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, et al. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res 2009;19:167-75.
12. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81. (Pubitemid 36152495)
13. Brummendorf TH, Cortes JE, Kantarjian H, Gambacorti-Passerini C, Baccarani M, Kim D, et al. Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). J Clin Oncol 2011;29 Suppl:15s; abstr. 6535.
14. Gambacorti-Passerini C, Kim D-W, Turkina A, Masszi T, Assouline S, Durrant S, et al. Bosutinib (SKI-606) as second-line therapy for chronic phase chronic myeloid leukemia (CP CML) following imatinib failure: analyses of cross-intolerance and response by prior response to imatinib. In: Proceedings of the 16th Congress of the European Hematology Association; 2011 Jun 9-12; London, UK. Abstract nr 0146.
15. Gambacorti-Passerini C, Cortes JE, Khoury HJ, Baccarani M, Kantarjian H, Chandy M, et al. Safety and efficacy of bosutinib in patientswith AP and BP CML and Ph+ ALL following resistance/intolerance to imatinib and other TKIs: update from study SKI-200. J Clin Oncol 2010;28 Suppl:15s; abstr. 6509.
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Bosutinib (SKI-606) Investigator's Brochure. August 2005.
18. Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65:5358-64. (Pubitemid 40827349)
19. Lara PN Jr, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 2009;20:179-84.
20. Tabernero J, Cervantes A, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007;25:3520.
21. Mackay HJ, Au HJ, McWhirter E, Alcindor T, Jarvi A, Macalpine K, et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs 2011 Mar 12. [Epub ahead of print].
22. Renouf DJ, Moore MJ, Hedley D, Gill S, Jonker D, Chen E, et al. Aphase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Invest New Drugs 2010 Dec 18. [Epub ahead of print].
23. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61. (Pubitemid 40053752)
24. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91.
25. Nallapareddy S, Arcaroli J, Touban B, Tan A, Foster NR, Erlichman C, et al. A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer. Gastrointestinal Cancers Symposium 2010; abstr. 165.
26. Eng C, Kopetz S, Morris J, Malik Z, Stewart D, Chang H-y, et al. Phase II study of the novel oral Src-kinase inhibitor, AZD0530, in previously treated advanced colorectal cancer patients [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research. 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract nr LB-76.
27. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1387-94.
28. Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, et al. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multitargeted kinase inhibitor. Cancer Chemother Pharmacol 2008;62:1065-74.
29. Rajeshkumar NV, Tan AC, De Oliveira E, Womack C, Wombwell H, Morgan S, et al. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009;15:4138-46.
30. Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol 2007;8:R255.
31. Campone M, Bondarenko I, Brincat S, Epstein RJ, Munster PN, Dubois E, et al. Preliminary results of a phase 2 study of bosutinib (SKI-606), a dual Src/Abl kinase inhibitor, in patients with advanced breast cancer. Breast Cancer Res Treat 2007;106. Abstract 6062.